Cure My Disease

Don't miss your cure!

 Log in / Sign up

New antibiotic CRS3123 takes on c. diff in early trial

NCT ID NCT04781387

Completed Disease control Sponsor: Crestone, Inc Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 study tested an experimental antibiotic called CRS3123 against the standard treatment vancomycin for Clostridioides difficile infection (C. diff). 43 adults with a first episode or first recurrence of C. diff took either CRS3123 or vancomycin for 10 days. The main goal was to see if CRS3123 could safely cure the infection as effectively as vancomycin.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
CRS3123 (an experimental antibiotic taken by mouth)
What this could lead to
If successful, this could lead to a new treatment option for C. difficile infection, potentially with fewer side effects or less risk of recurrence.
What could go wrong
This is a small, early-phase trial with only 43 participants. The drug may not prove more effective than existing treatments, and safety data is limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLOSTRIDIOIDES DIFFICILE INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Clostridium difficile colitis Clostridium infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLOSTRIDIOIDES DIFFICILE INFECTION

Contacts and locations

Locations

  • 101

    San Antonio, Texas, 78229, United States

  • 104

    Cedar Park, Texas, 78613, United States

  • 110

    Idaho Falls, Idaho, 83404, United States

  • 114

    Uniontown, Pennsylvania, 15401, United States

  • 116

    Calgary, Alberta, T2N2T9, Canada

  • 117

    Lancaster, California, 93534, United States

  • 120

    London, Ontario, N6A 4V2, Canada

  • 122

    Miami, Florida, 33144, United States

  • 123

    Houston, Texas, 77079, United States

  • 128

    Butte, Montana, 59701, United States

  • 129

    Winfield, Illinois, 60190, United States

  • 130

    Royal Oak, Michigan, 48073, United States

  • 131

    Fullerton, California, 92835, United States

  • 134

    The Bronx, New York, 10467, United States

  • 138

    Orange, California, 92868, United States

  • 139

    Weldon Spring, Missouri, 63304, United States

  • 140

    Marietta, Georgia, 30060, United States

  • 143

    Mission Hills, California, 91345, United States

  • 146

    Miami, Florida, 33125, United States

  • 147

    Chapel Hill, North Carolina, 27514, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.